Received by email:

File: 2018-06-29 News Release - Greece Acquisiton.docx

Kaneh Bosm BioTechnology Inc. 
810 - 789 West Pender Street 
Vancouver BC V6C 1H2 
Tel: 604.687.2308 

NOT FOR DISSEMINATION IN THE UNITED STATES
NEWS RELEASE 

KANEH BOSM EXPANDS CULTIVATION INTO EUROPE WITH GREECE ACQUISITION

VANCOUVER, British Columbia, June 29, 2018 (Globe Newswire)- Kaneh Bosm BioTechnolgy Inc. (CSE:KBB) ("Kaneh Bosm" or t
--->he "Company") is pleased to announce that it has entered into a definitive agreement (the "Agreement") with EU Cannabi
--->s Corp. ("EU Cannabis") to acquire 100% of EU Cannabis' issued and outstanding shares. 
EU Cannabis has an option to acquire a 90% working interest in industrial hemp licenses ("Licenses") held by Cannatec 
--->Greece A.E. ("Cannatec"). Cannatech currently holds three Licenses covering a total of 16 acres situated within the Gr
--->eek prefecture of Imathia. These Licenses were granted to Cannatec by the Hellenic Republic Ministry of Agricultural D
--->evelopment and Food and permit EU Cannabis to cultivate, manufacture, distribute and export industrial hemp and its ma
--->ny cannabidiol ("CBD") derived extracts. Greece boasts over 300 days of unadulterated sunshine per year, resulting in 
--->attractive climate for outdoor industrial hemp cultivation. 
Eugene Beukman, CEO of Kaneh Bosm states, "EU Cannabis is equipped with considerable regional and industry experience 
--->within the Southern European theatre. Leveraging EU Cannabis' deep-seated understanding of regional business practices
---> and export regulations, coupled with Kaneh Bosm's expansive distribution network, will allow for continued penetratio
--->n of the European Union's burgeoning CBD markets and the insatiable appetite for natural medical products."
The alignment of the Company's existing distribution channels, revolutionary ADM retail system along with EU Cannabis'
---> robust extraction capabilities will assist is appeasing an expanding appetite for functional CBD products within the 
--->European Union. 
Under the terms of the Agreement, the Company will pay US$250,000, and it will issue 18 million common shares. 
On behalf of the Board of Directors of Kaneh Bosm Biotechnology Inc.
"Michael Martinz"
Michael Martinz
President, Director 
mmartinz@kanehbosmbiotech.com 

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE. 

This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the w
--->ords "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and simila
--->r expressions are intended to identify forward-looking statements. Although the Company believes that the expectations
---> and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed
---> on the forward looking statements because the Company can give no assurance that they will prove to be correct. Since
---> forward-looking statements address future events and conditions, by their very nature they involve inherent risks and
---> uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materiall
--->y from those currently anticipated due to a number of factors and risks including various risk factors discussed in th
--->e Company's disclosure documents which can be found under the Company's profile on www.sedar.com